News

Toulouse, France, September 29th, 2017 – Genoskin launches a new skin model to study skin inflammation. InflammaSkin® is a T cell-driven skin inflammation model with a psoriasis-like phenotype. The pharmacological validation of this psoriasis skin model will be presented at the 47th annual ESDR meeting 2017 (Poster 100) on September 27th to 30th, 2017. Don't hesitate to visit us in booth #9. Why immunocompetent skinRead more

New study on effects of indoor air pollution on human skin uses NativeSkin® models Indoor air pollution may alter human skin. A study that was recently published in Scientific Reports  shows that volatile organic compounds target the cellular mechanism that eliminates damaged proteins. The study uses Genoskin's NativeSkin® model to study the effects of indoor air pollution on human skin andRead more

HistoSkin® FFPE skin tissue blocks In order to help our customers conduct the skin research they need, Genoskin launches HistoSkin® to simplify access to FFPE human skin tissue blocks and sections for studies and analysis. HistoSkin® offers a wide range of fully characterized FFPE tissue blocks and sections and provides new research opportunities involving human skin. A wide selection of donors Every year, Genoskin collects a wide range

Read more

On March 9th, 2017,  Genoskin won the Award for Innovation at the CEO Company Challenge meeting in Colomiers, France. The award highlights local companies that have special merit in the area of export, innovation and job creation. Genoskin wins CEO Award for Innovation In the light of today’s challenging economic context, the CEO West-Toulouse Company Club aims to highlight the driving efforts of

Read more

Genoskin obtains US patent for skin models Genoskin is pleased to announce the approval of a US patent for our "system for the maintenance and survival of skin biopsies in transport and its applications". The patent describes our method to transform human skin biopsies in ready-to-use and functional ex vivo skin models. The human skin biopsies that are used in our modelsRead more

“Genoskin is the first biotechnology company in the area to obtain the ISO9001:2015 certification” says Mr Bonzom. “This confirms their position as a trustworthy preclinical research partner for customers developing new drugs and products that need to be tested on human skin.”